EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High-Sensitivity Troponin I Measurement in a Large Contemporary Cohort: Implications for Clinical Care

Daniel Esau, Peter Nord, Beth L Abramson

Cardiology · 2025

DOI: 10.1159/000543403 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiology, 2025. Verfasst von Daniel Esau und 2 weiteren Autor:innen. Beteiligte Einrichtung: Royal Jubilee Hospital, Victoria, British Columbia, Canada. Hauptthemen laut MEDLINE: Troponin I, Cardiovascular Diseases. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Contemporary methods of cardiovascular (CV) risk stratification are frequently inaccurate. Biomarkers such as high-sensitivity troponin I (hsTnI) have the potential to improve risk stratification. However, uncertainties exist regarding factors that determine hsTnI concentration. Our aim was to investigate the prevalence of elevated hsTnI in a large contemporary Canadian cohort and describe the effect of comorbidities on hsTnI concentration.

Methods

We report a large dataset of 41,602 visits in which hsTnI was measured routinely in ambulatory outpatients. hsTnI was remeasured in 28% of patients, with a mean time between measurements of 387 days (IQR 364–441). Low-, medium-, and high-risk categories were created based on hsTnI cutoffs for each sex. Laboratory data, blood pressure, and anthropomorphic measures were extracted from the electronic medical record.

Results

Remeasurement of hsTnI did not change risk category in 92.7% of cases. Male sex, higher HDL-C, higher Hgb A1c, decreasing eGFR, and increasing systolic blood pressure were significant predictors of increased hsTnI. High non-HDL-C and the use of statins were associated with lower hsTnI. The inverse relationship between hsTnI and non-HDL-C was partially corrected when the confounding effect of statin therapy was considered. Model fit was poor (adjusted R-squared = 0.0091).

Conclusion

Traditional CV risk factors were predictors of serum hsTnI levels; however, a significant amount of the variance in hsTnI cannot be explained by these factors alone. This suggests that hsTnI adds additional information that is not provided by traditional risk stratification methods and supports ongoing study of hsTnI as a biomarker for CV risk stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Troponin ICardiovascular DiseasesHumansMaleFemaleBiomarkersAgedMiddle AgedRisk AssessmentCanadaCohort StudiesRisk Factors

Stichwörter der Autor:innen

Cardiovascular diseaseHigh-sensitivity troponin IPublic healthRisk stratificationTroponin

Substanzen

Troponin IBiomarkers

Autor:innen und Institutionen

  • Royal Jubilee Hospital, Victoria, British Columbia, Canada.
  • Division of Community General Internal Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • MedCan, Toronto, Ontario, Canada.
  • Division of Cardiology, University of Toronto, St. Michael's Hospital, Toronto, Ontario, Canada, beth.abramson@unityhealth.to.

Zitieren

APA

Esau, D., Nord, P., & Abramson, B. L. (2025). High-Sensitivity Troponin I Measurement in a Large Contemporary Cohort: Implications for Clinical Care. Cardiology. https://doi.org/10.1159/000543403

Vancouver

Esau D, Nord P, Abramson BL. High-Sensitivity Troponin I Measurement in a Large Contemporary Cohort: Implications for Clinical Care. Cardiology. 2025. doi:10.1159/000543403

BibTeX
@article{Esau2025,
  author = {Esau, Daniel and Nord, Peter and Abramson, Beth L},
  title = {High-Sensitivity Troponin I Measurement in a Large Contemporary Cohort: Implications for Clinical Care},
  journal = {Cardiology},
  year = {2025},
  doi = {10.1159/000543403}
}
Kostenlos starten →